Successful treatment of a child with MEK inhibitor-induced acneiform eruption with low-dose isotretinoin.

Abstract

Selumetinib is a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor (MEKi) approved to treat inoperable plexiform neurofibromas and used off-label for low-grade gliomas. Acneiform eruptions are a known complication of MEKi use, and in some cases, may lead to paused, dose-reduced, or discontinued therapy. Isotretinoin has been reported as an effective treatment for acneiform eruptions secondary to targeted therapies, primarily in the adult population. Here we describe a pediatric patient with a severe acneiform eruption secondary to selumetinib who was successfully treated with low-dose isotretinoin when unresponsive to conventional therapies.

• Authors: Rohit Gupta, Megan F Craddock
• Journal: Pediatric dermatology (Pediatr Dermatol) Vol. 39 Issue 4 Pg. 646-647 (Jul 2022) ISSN: 1525-1470 [Electronic] United States
• PMID: 35896172 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2022 Wiley Periodicals LLC.

Chemical References

• Protein Kinase Inhibitors
• Mitogen-Activated Protein Kinase Kinases
• Isotretinoin

Topics

• Acneiform Eruptions (chemically induced, drug therapy)
• Child
• Humans
• Isotretinoin (therapeutic use)
• Mitogen-Activated Protein Kinase Kinases (antagonists & inhibitors)
• Neurofibroma, Plexiform
• Protein Kinase Inhibitors (adverse effects)